Biologics Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2027, at CAGR of XX% during forecast period of 2019 to 2027. Biologics are drugs made from complex molecules manufactured using living plants, microorganisms or animal cells. Biologics drugs market has been exhibiting an aggressive competition divided among a handful of household organizations and count of the world’s best pharmaceutical companies. There are some examples of biologics such as Lantus (insulin glargine), Humira (adalimumab), Herceptin (trastuzumab), Avastin (bevacizumab) and Botox (onabotulinumtoxina). Biologics have witnessed millions of dollars put in by pharmaceutical behemoths like Sandoz, AstraZenca, Novartis, and Eli Lilly and Co. and others. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Biologics Market Drivers and Restrains In the past five years, over US$ 1.5 billion have been invested by top 10 pharmaceutical giants which have interpreted into capacity expansion and focused research and development. Pharmaceutical companies are earning strong revenues through best prices value increased in their profit margins XX %. Factors like product approvals and the ability of biologics to effectively treat significantly complex diseases, which was close to incredible earlier, have been key for biologics market growth. Pharmaceutical companies patenting biologics products have been projected to make healthy gains during the forecast period. With the vigorous growth in the biopharmaceutical industry, an over 14% of biomolecules that enter phase I of clinical trials have been expected to be likely approved as a drug. Growing annual product approvals and strong biologics channel has been an indication of a robust development of the world biologics market. For example, the anti-inflammatory drug Humira is not only the best-selling drugs, but it is also one of the best-selling drugs globally. But, high capital investment essential for research and development could hinder the demand in the international biologics market. Only biopharmaceutical companies have been observed to enter the market because of a costly initial setup. A success product launch primarily requires an over US$1.0 billion investment and takes nearly 9 years. Furthermore, the regulatory approval of biologics is quite detailed since the molecules are complex. Manufacturers in the Biologics are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. Biologics Market Segmentation Analysis In terms of market segmentation biologics market segmented into two types such as product, application and region. In terms of product type market is sub segmented into five type such monoclonal antibodies, vaccines, recombinant hormones/proteins, cell therapy, gene therapy. On other hand by application market classified as oncology, infectious diseases, immunology and autoimmune diseases. In type of product monoclonal antibodies segment is expected to grow at the highest XX% CAGR during the forecast period. Because of extensive growth is credited to the increasing demand for personalized therapies in various regions. Additionally, extensive researches in antibodies to discover targeted therapies for a variety of diseases, like different types of infections, cancers, and various immunological disorders, are projected to propel the market. Biologics Market Regional Analysis On the basis of region, Biologics Market divided into five region such as Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among all the regions, North America had hold the largest market share in 2018 and is projected to lead the market during the forecast period. Because of, growth in this regional market is attributed to intensive research and development activities, novel drug formulations, and a large number of clinical trials focused on large-molecule drug discovery. Furthermore, Asia Pacific is expected to be the second largest market over the forecast period and nearly follow by North America in terms of profits. The objective of the report is to present comprehensive analysis of Biologics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Biologics Market dynamics, structure by analyzing the market segments, and project the Biologics Market size. Clear representation of competitive analysis of key players by Biologics Type, price, financial position, product portfolio, growth strategies, and regional presence in the Biologics Market make the report investor’s guide.
Scope of the Biologics Market
Biologics Market, by Product• Monoclonal Antibodies • Vaccines • Recombinant Hormones/Proteins • Cell Therapy • Gene Therapy
Biologics Market, by Application• Oncology • Infectious Diseases • Immunology • Autoimmune Diseases
Biologics Market, by Region• Asia Pacific • North America • Europe • Latin America • Middle East Africa
Biologics Market, Major Players• Sandoz • Pfizer • Teva Pahrmaceutical • Celltrion • Biocon • Amgen • Samsung Biologics • Mylan • Dr. Reddy's Laboratories • Stada Arzneimittel AG • Pernix Therapeutics • Purdue Pharma L.P. • Sanofi Pasteur • SkyePharma • Takeda Pharmaceutical Company • Roche Global Oral Contraceptive Pills Market
Table of Contents
Biologics Market1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 126.96.36.199. Secondary data 188.8.131.52. Secondary Sources 2.3.2. Primary Research 184.108.40.206. Data from Primary Sources 220.127.116.11. Breakdown of Primary Sources 3. Executive Summary: Global Biologics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Biologics Market Analysis and Forecast 6.1. Global Biologics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Biologics Market Analysis and Forecast, By Application 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Biologics Market Value Share Analysis, By Application 7.4. Global Biologics Market Size (US$ Bn) Forecast, By Application 7.5. Global Biologics Market Analysis, By Application 7.6. Global Biologics Market Attractiveness Analysis, By Application 8. Global Biologics Market Analysis and Forecast, By Product 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Biologics Market Value Share Analysis, By Product 8.4. Global Biologics Market Size (US$ Bn) Forecast, By Product 8.5. Global Biologics Market Analysis, By Product 8.6. Global Biologics Market Attractiveness Analysis, By Product 9. Global Biologics Market Analysis, by Region 9.1. Global Biologics Market Value Share Analysis, by Region 9.2. Global Biologics Market Size (US$ Bn) Forecast, by Region 9.3. Global Biologics Market Attractiveness Analysis, by Region 10. North America Biologics Market Analysis 10.1. Key Findings 10.2. North America Biologics Market Overview 10.3. North America Biologics Market Value Share Analysis, By Application 10.4. North America Biologics Market Forecast, By Application 10.4.1. Oncology 10.4.2. Infectious Diseases 10.4.3. Immunology 10.4.4. Autoimmune Diseases 10.5. North America Biologics Market Value Share Analysis, By Product 10.6. North America Biologics Market Forecast, By Product 10.6.1. Monoclonal Antibodies 10.6.2. Vaccines 10.6.3. Recombinant Hormones/Proteins 10.6.4. Cell Therapy 10.6.5. Gene Therapy 10.7. North America Biologics Market Value Share Analysis, by Country 10.8. North America Biologics Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Biologics Market Analysis, by Country 10.10. U.S. Biologics Market Forecast, By Application 10.10.1. Oncology 10.10.2. Infectious Diseases 10.10.3. Immunology 10.10.4. Autoimmune Diseases 10.11. U.S. Biologics Market Forecast, By Product 10.11.1. Monoclonal Antibodies 10.11.2. Vaccines 10.11.3. Recombinant Hormones/Proteins 10.11.4. Cell Therapy 10.11.5. Gene Therapy 10.12. Canada Biologics Market Forecast, By Application 10.12.1. Oncology 10.12.2. Infectious Diseases 10.12.3. Immunology 10.12.4. Autoimmune Diseases 10.13. Canada Biologics Market Forecast, By Product 10.13.1. Monoclonal Antibodies 10.13.2. Vaccines 10.13.3. Recombinant Hormones/Proteins 10.13.4. Cell Therapy 10.13.5. Gene Therapy 10.14. North America Biologics Market Attractiveness Analysis 10.14.1. By Application 10.14.2. By Product 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Biologics Market Analysis 11.1. Key Findings 11.2. Europe Biologics Market Overview 11.3. Europe Biologics Market Value Share Analysis, By Application 11.4. Europe Biologics Market Forecast, By Application 11.4.1. Oncology 11.4.2. Infectious Diseases 11.4.3. Immunology 11.4.4. Autoimmune Diseases 11.5. Europe Biologics Market Value Share Analysis, By Product 11.6. Europe Biologics Market Forecast, By Product 11.6.1. Monoclonal Antibodies 11.6.2. Vaccines 11.6.3. Recombinant Hormones/Proteins 11.6.4. Cell Therapy 11.6.5. Gene Therapy 11.7. Europe Biologics Market Value Share Analysis, by Country 11.8. Europe Biologics Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Biologics Market Analysis, by Country 11.10. Germany Biologics Market Forecast, By Application 11.10.1. Oncology 11.10.2. Infectious Diseases 11.10.3. Immunology 11.10.4. Autoimmune Diseases 11.11. Germany Biologics Market Forecast, By Product 11.11.1. Monoclonal Antibodies 11.11.2. Vaccines 11.11.3. Recombinant Hormones/Proteins 11.11.4. Cell Therapy 11.11.5. Gene Therapy 11.12. U.K. Biologics Market Forecast, By Application 11.12.1. Oncology 11.12.2. Infectious Diseases 11.12.3. Immunology 11.12.4. Autoimmune Diseases 11.13. U.K. Biologics Market Forecast, By Product 11.13.1. Monoclonal Antibodies 11.13.2. Vaccines 11.13.3. Recombinant Hormones/Proteins 11.13.4. Cell Therapy 11.13.5. Gene Therapy 11.14. France Biologics Market Forecast, By Application 11.14.1. Oncology 11.14.2. Infectious Diseases 11.14.3. Immunology 11.14.4. Autoimmune Diseases 11.15. France Biologics Market Forecast, By Product 11.15.1. Monoclonal Antibodies 11.15.2. Vaccines 11.15.3. Recombinant Hormones/Proteins 11.15.4. Cell Therapy 11.15.5. Gene Therapy 11.16. Italy Biologics Market Forecast, By Application 11.16.1. Oncology 11.16.2. Infectious Diseases 11.16.3. Immunology 11.16.4. Autoimmune Diseases 11.17. Italy Biologics Market Forecast, By Product 11.17.1. Monoclonal Antibodies 11.17.2. Vaccines 11.17.3. Recombinant Hormones/Proteins 11.17.4. Cell Therapy 11.17.5. Gene Therapy 11.18. Spain Biologics Market Forecast, By Application 11.18.1. Oncology 11.18.2. Infectious Diseases 11.18.3. Immunology 11.18.4. Autoimmune Diseases 11.19. Spain Biologics Market Forecast, By Product 11.19.1. Monoclonal Antibodies 11.19.2. Vaccines 11.19.3. Recombinant Hormones/Proteins 11.19.4. Cell Therapy 11.19.5. Gene Therapy 11.20. Rest of Europe Biologics Market Forecast, By Application 11.20.1. Oncology 11.20.2. Infectious Diseases 11.20.3. Immunology 11.20.4. Autoimmune Diseases 11.21. Rest of Europe Biologics Market Forecast, By Product 11.21.1. Monoclonal Antibodies 11.21.2. Vaccines 11.21.3. Recombinant Hormones/Proteins 11.21.4. Cell Therapy 11.21.5. Gene Therapy 11.22. Europe Biologics Market Attractiveness Analysis 11.22.1. By Application 11.22.2. By Product 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Biologics Market Analysis 12.1. Key Findings 12.2. Asia Pacific Biologics Market Overview 12.3. Asia Pacific Biologics Market Value Share Analysis, By Application 12.4. Asia Pacific Biologics Market Forecast, By Application 12.4.1. Oncology 12.4.2. Infectious Diseases 12.4.3. Immunology 12.4.4. Autoimmune Diseases 12.5. Asia Pacific Biologics Market Value Share Analysis, By Product 12.6. Asia Pacific Biologics Market Forecast, By Product 12.6.1. Monoclonal Antibodies 12.6.2. Vaccines 12.6.3. Recombinant Hormones/Proteins 12.6.4. Cell Therapy 12.6.5. Gene Therapy 12.7. Asia Pacific Biologics Market Value Share Analysis, by Country 12.8. Asia Pacific Biologics Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Biologics Market Analysis, by Country 12.10. China Biologics Market Forecast, By Application 12.10.1. Oncology 12.10.2. Infectious Diseases 12.10.3. Immunology 12.10.4. Autoimmune Diseases 12.11. China Biologics Market Forecast, By Product 12.11.1. Monoclonal Antibodies 12.11.2. Vaccines 12.11.3. Recombinant Hormones/Proteins 12.11.4. Cell Therapy 12.11.5. Gene Therapy 12.12. India Biologics Market Forecast, By Application 12.12.1. Oncology 12.12.2. Infectious Diseases 12.12.3. Immunology 12.12.4. Autoimmune Diseases 12.13. India Biologics Market Forecast, By Product 12.13.1. Monoclonal Antibodies 12.13.2. Vaccines 12.13.3. Recombinant Hormones/Proteins 12.13.4. Cell Therapy 12.13.5. Gene Therapy 12.14. Japan Biologics Market Forecast, By Application 12.14.1. Oncology 12.14.2. Infectious Diseases 12.14.3. Immunology 12.14.4. Autoimmune Diseases 12.15. Japan Biologics Market Forecast, By Product 12.15.1. Monoclonal Antibodies 12.15.2. Vaccines 12.15.3. Recombinant Hormones/Proteins 12.15.4. Cell Therapy 12.15.5. Gene Therapy 12.16. ASEAN Biologics Market Forecast, By Application 12.16.1. Oncology 12.16.2. Infectious Diseases 12.16.3. Immunology 12.16.4. Autoimmune Diseases 12.17. ASEAN Biologics Market Forecast, By Product 12.17.1. Monoclonal Antibodies 12.17.2. Vaccines 12.17.3. Recombinant Hormones/Proteins 12.17.4. Cell Therapy 12.17.5. Gene Therapy 12.18. Rest of Asia Pacific Biologics Market Forecast, By Application 12.18.1. Oncology 12.18.2. Infectious Diseases 12.18.3. Immunology 12.18.4. Autoimmune Diseases 12.19. Rest of Asia Pacific Biologics Market Forecast, By Product 12.19.1. Monoclonal Antibodies 12.19.2. Vaccines 12.19.3. Recombinant Hormones/Proteins 12.19.4. Cell Therapy 12.19.5. Gene Therapy 12.20. Asia Pacific Biologics Market Attractiveness Analysis 12.20.1. By Application 12.20.2. By Product 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Biologics Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Biologics Market Overview 13.3. Middle East & Africa Biologics Market Value Share Analysis, By Application 13.4. Middle East & Africa Biologics Market Forecast, By Application 13.4.1. Oncology 13.4.2. Infectious Diseases 13.4.3. Immunology 13.4.4. Autoimmune Diseases 13.5. Middle East & Africa Biologics Market Value Share Analysis, By Product 13.6. Middle East & Africa Biologics Market Forecast, By Product 13.6.1. Monoclonal Antibodies 13.6.2. Vaccines 13.6.3. Recombinant Hormones/Proteins 13.6.4. Cell Therapy 13.6.5. Gene Therapy 13.7. Middle East & Africa Biologics Market Value Share Analysis, by Country 13.8. Middle East & Africa Biologics Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Biologics Market Analysis, by Country 13.10. GCC Biologics Market Forecast, By Application 13.10.1. Oncology 13.10.2. Infectious Diseases 13.10.3. Immunology 13.10.4. Autoimmune Diseases 13.11. GCC Biologics Market Forecast, By Product 13.11.1. Monoclonal Antibodies 13.11.2. Vaccines 13.11.3. Recombinant Hormones/Proteins 13.11.4. Cell Therapy 13.11.5. Gene Therapy 13.12. South Africa Biologics Market Forecast, By Application 13.12.1. Oncology 13.12.2. Infectious Diseases 13.12.3. Immunology 13.12.4. Autoimmune Diseases 13.13. South Africa Biologics Market Forecast, By Product 13.13.1. Monoclonal Antibodies 13.13.2. Vaccines 13.13.3. Recombinant Hormones/Proteins 13.13.4. Cell Therapy 13.13.5. Gene Therapy 13.14. Rest of Middle East & Africa Biologics Market Forecast, By Application 13.14.1. Oncology 13.14.2. Infectious Diseases 13.14.3. Immunology 13.14.4. Autoimmune Diseases 13.15. Rest of Middle East & Africa Biologics Market Forecast, By Product 13.15.1. Monoclonal Antibodies 13.15.2. Vaccines 13.15.3. Recombinant Hormones/Proteins 13.15.4. Cell Therapy 13.15.5. Gene Therapy 13.16. Middle East & Africa Biologics Market Attractiveness Analysis 13.16.1. By Application 13.16.2. By Product 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Biologics Market Analysis 14.1. Key Findings 14.2. South America Biologics Market Overview 14.3. South America Biologics Market Value Share Analysis, By Application 14.4. South America Biologics Market Forecast, By Application 14.4.1. Oncology 14.4.2. Infectious Diseases 14.4.3. Immunology 14.4.4. Autoimmune Diseases 14.5. South America Biologics Market Value Share Analysis, By Product 14.6. South America Biologics Market Forecast, By Product 14.6.1. Monoclonal Antibodies 14.6.2. Vaccines 14.6.3. Recombinant Hormones/Proteins 14.6.4. Cell Therapy 14.6.5. Gene Therapy 14.7. South America Biologics Market Value Share Analysis, by Country 14.8. South America Biologics Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Biologics Market Forecast, By Application 14.9.1. Oncology 14.9.2. Infectious Diseases 14.9.3. Immunology 14.9.4. Autoimmune Diseases 14.10. Brazil Biologics Market Forecast, By Product 14.10.1. Monoclonal Antibodies 14.10.2. Vaccines 14.10.3. Recombinant Hormones/Proteins 14.10.4. Cell Therapy 14.10.5. Gene Therapy 14.11. Mexico Biologics Market Forecast, By Application 14.11.1. Oncology 14.11.2. Infectious Diseases 14.11.3. Immunology 14.11.4. Autoimmune Diseases 14.12. Mexico Biologics Market Forecast, By Product 14.12.1. Monoclonal Antibodies 14.12.2. Vaccines 14.12.3. Recombinant Hormones/Proteins 14.12.4. Cell Therapy 14.12.5. Gene Therapy 14.13. Rest of South America Biologics Market Forecast, By Application 14.13.1. Oncology 14.13.2. Infectious Diseases 14.13.3. Immunology 14.13.4. Autoimmune Diseases 14.14. Rest of South America Biologics Market Forecast, By Product 14.14.1. Monoclonal Antibodies 14.14.2. Vaccines 14.14.3. Recombinant Hormones/Proteins 14.14.4. Cell Therapy 14.14.5. Gene Therapy 14.15. South America Biologics Market Attractiveness Analysis 14.15.1. By Application 14.15.2. By Product 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 18.104.22.168. M&A by Regions, Investment and Applications 22.214.171.124. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Sandoz 126.96.36.199. Company Overview 188.8.131.52. Financial Overview 184.108.40.206. Product Portfolio 220.127.116.11. Business Strategy 18.104.22.168. Recent Developments 22.214.171.124. Company Footprint 15.3.2. Pfizer 15.3.3. Teva Pahrmaceutical 15.3.4. Celltrion 15.3.5. Biocon 15.3.6. Amgen 15.3.7. Samsung Biologics 15.3.8. Mylan 15.3.9. Dr. Reddy's Laboratories 15.3.10. Stada Arzneimittel AG 15.3.11. Pernix Therapeutics 15.3.12. Purdue Pharma L.P. 15.3.13. Sanofi Pasteur 15.3.14. SkyePharma 15.3.15. Takeda Pharmaceutical Company 15.3.16. Roche 16. Primary Key Insights